Understanding how RNA splicing affects the spread of aggressive cancers.
Elucidating the role of RNA splicing in the metastatic seeding and outgrowth of aggressive cancers.
This study is looking at how a specific RNA molecule affects the spread of breast cancer, with the hope of finding new ways to treat patients by targeting the weaknesses in tumors that spread.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10949072 on NIH RePORTER |
What this research studies
This research investigates the role of RNA splicing in the process of cancer metastasis, particularly focusing on breast cancer. It aims to uncover how certain RNA molecules, specifically the lncRNA BORG, interact with proteins to influence the behavior of cancer cells that spread to other parts of the body. By studying these mechanisms, the research seeks to identify potential weaknesses in metastatic tumors that could be targeted for new therapies. Patients may benefit from insights that could lead to more effective treatments for aggressive cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with aggressive forms of breast cancer, particularly those experiencing or at risk of metastasis.
Not a fit: Patients with non-aggressive or early-stage breast cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that specifically target metastatic breast cancer.
How similar studies have performed: Other research has shown promising results in targeting RNA splicing mechanisms in cancer, suggesting that this approach could be effective.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Parker, Kimberly — Dana-Farber Cancer Inst
- Study coordinator: Parker, Kimberly
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.